Last reviewed · How we verify
Non-nucleoside reverse transcriptase inhibitor
is a non-nucleoside reverse transcriptase inhibitor marketed by GlaxoSmithKline for the treatment of HIV. The drug's key composition patent is set to expire in 2028, providing a period of market exclusivity. The primary risk to the drug's market position is the potential increase in competition following patent expiration.
At a glance
| Generic name | Non-nucleoside reverse transcriptase inhibitor |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen (PHASE4)
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old (PHASE2, PHASE3)
- Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017) (PHASE3)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver Disease
- Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients (PHASE4)
- The Effects of Ageing on the 'Pharmacokinetic and Clinical Observations in People Over Fifty'
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: